Tag Archives: surfactant
Risk factors of preterm infants with CPAP intubated for mechanical ventilation
O. Borysiuk1,2*, O. Matsyura1, L. Besh1, Y. Dubrovna2
1Department of Pediatrics No. 2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine;
2LRC CNE “Lviv Regional Clinical Hospital,” Lviv, Ukraine;
*e-mail: olenabora@gmail.com
Received: 09 May 2023; Revised: 07 June 2023;
Accepted: 11 June 2023; Available on-line: 11 July 2023
Early use of continuous positive airway pressure (CPAP) is equal to the prophylactic administration of a surfactant to prevent neonatal respiratory distress syndrome (nRDS) in high-risk infants. However, almost half of the smallest infants still require intubation and mechanical ventilation in the first 72 hours after birth. It is known that ineffective initial CPAP is associated with a poorer prognosis. Therefore, the search for reliable prognostic risk factors for ineffective CPAP in very preterm neonates whose respiratory support is started with CPAP is still relevant today. The results of a retrospective cohort study conducted at the Lviv Regional Clinical Hospital (Ukraine), which included 151 children with birth weight <1500 g and gestational age <32 weeks, showed that CPAP failure occurred at a median age of five hours in 31% of infants initially treated with CPAP and average (SD) FiO2, while the failure point was 0.48 (0.15). The prevalence of the main risk factors for severe nRDS did not differ significantly between two groups (CPAP success and CPAP failure). The risk of CPAP failure was significantly associated with surfactant treatment (OR – 7.46; 95% CI: 2.3–24.2), severe RDS (OR – 12.17; 95% CI: 3.8–39.3), requirement in resuscitation after birth (OR – 3.10; 95% CI: 1.2–8.1), initial CPAP pressure (OR – 0.38; 95% CI: 0.15–0.99). Earlier administration of exogenous surfactant to children at high risk of developing severe RDS could prevent the need for mechanical ventilation.
Practical development of laboratory of biologics technology of the Palladin Institute of Biochemistry of NAS of Ukraine for the period 1991-2010
G. G. Lugovska, R. P. Vynogradova, N. E. Lugovska,
I. G. Chernysh, S. P. Yurasova, V. M. Danilova
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: tto@biochem.kiev.ua
The paper presents the results of inventive activity of the Laboratory of Biologics Technology of the Palladin Institute of Biochemistry, NAS of Ukraine, under the leadership of Z.M.Datsenko, Cand.Sc. (Biol.), during 1991-2010. The laboratory researchers have developed new technologies for production of medicines of lipid-protein nature, which are based on endogenous complexes of biologically active substances included in the composition of biomembranes of different origin. The researchers have created new technologies for drug PANTOCRINE (for injections and oral administration) from antlers of deers and horns of farm animals that have significantly higher biological activity compared with the commercial drug. They have also created new biologically active drugs from antlers with a specific action: HIPPOCAMP, reducing blood pressure in various forms of hypertension, and PANTERON – biological regulator of synthesis of steroid hormones. Further the researchers have developed technologies for obtaining biologically active complexes of various specific action from marine organisms (calamari, clams mussels, shellfish): CALMOFIL and MOLUFIL, therapeutic agents for replacement therapy of surfactant system of the lungs; FILOMEK, the agent for prophylaxis and treatment of a human reproductive system disorders; MOLUSTERON, the glicolipopeptide complex, three individual physiologically active compositions being differentially obtained from the latter: lipopeptide composition – for treatment of hypertension, nucleopeptide one – for treatment of hormonal disorders, and phospholipid – for treatment of lung diseases under the surfactant shortage.